Congenital Adrenal Hyperplasia (CAH) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Congenital Adrenal Hyperplasia (CAH) Emerging Therapy and TPP Insights

Thelansis’s “Congenital Adrenal Hyperplasia (CAH) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Congenital Adrenal Hyperplasia (CAH) Overview

Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive adrenal steroidogenesis disorders, with 21-hydroxylase deficiency caused by CYP21A2 mutations accounting for over 90% of cases, disrupting cortisol and aldosterone biosynthesis while redirecting steroid precursors toward androgen excess. Disease severity spans classic salt-wasting CAH presenting neonatally with adrenal crisis, hyponatremia, hyperkalemia, and virilization, through simple virilizing and non-classic forms manifesting with premature adrenarche, hirsutism, and subfertility. Newborn screening via 17-hydroxyprogesterone measurement enables early diagnosis, confirmed by genotyping and adrenal steroid profiling. Glucocorticoid replacement suppresses ACTH-driven androgen excess while restoring deficient cortisol; fludrocortisone addresses salt-wasting. Balancing glucocorticoid dosing remains clinically challenging, as under-replacement perpetuates androgen excess while over-replacement risks iatrogenic Cushing syndrome and growth suppression. The medical paradigm shifted with the FDA approval of Crenessity (crinecerfont), an oral CRF1 receptor antagonist indicated for classic CAH patients aged four and older. Crinecerfont directly reduces excessive ACTH and downstream adrenal androgens through a non-glucocorticoid mechanism, successfully enabling major reductions in daily steroid maintenance doses. Conversely, development of alternative CRF1 antagonists like tildacerfont has been entirely discontinued due to poor clinical efficacy. Preventing adrenal crisis through sick-day rules remains critical to optimizing lifelong patient outcomes.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Congenital Adrenal Hyperplasia (CAH) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026